« Return to News | CROs/Service Providers

InVentiv Expands REMS Business with ParagonRx Acquisition

Thursday, January 7, 2010 09:09 AM

Banking on the growing demand for risk evaluation and mitigation strategy services (REMS), New Jersey-based inVentiv Health acquired REMS consulting company ParagonRx for an undisclosed sum in a deal that was finalized December 31.

inVentiv, which provides marketing, communications and staffing to the pharmaceutical industry, launched its REMS business last August in response to a growing demand for these types of services to meet U.S. Food and Drug Administration (FDA) regulations. The FDA requires pharma companies to submit a  REMS for selected products. Companies failing to submit a suitable REMS may experience approval delays and other roadblocks.

"Driving safe and appropriate use of medicine and managing potential risks are key priorities for inVentiv's clients, and thus, we recently launched an integrated REMS offering to support these growing needs," said Blane Walter, chief executive officer of inVentiv Health. "Today we are significantly strengthening our REMS capabilities with the acquisition of ParagonRx, unquestionably one of the industry's top experts in risk mitigation. Their extensive experience in consultative REMS and safety services is an ideal complement to inVentiv Health's broad array of risk communications and REMS implementation services. The resulting combination will enable inVentiv to deliver a truly comprehensive REMS and risk management solution to our clients on a global basis through a single point of contact."

Based in Wilmington, Del., ParagonRx was founded in 2001 by former DuPont executive Jeffrey Fetterman and Gary Slatko, M.D., also a former pharma executive.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.